Proxy statement
Open the filing on sec.gov
Biomerica, Inc. (BMRA)
Nasdaq: BMRA · In Vitro & In Vivo Diagnostic Substances · Irvine, CA · filing with the SEC since 1995
The companyfiscal 2026, as filed
Revenue$4.5M-16.2%
Net income-$3.8M+24.1%
Earnings per share$-1.30+39.8%
Operating cash flow-$3.4M+11.0%
Cash$1.3M-45.5%
Debtn/a
Shareholders’ equity$2.6M-35.9%
Shares, diluted2,914,923+26.9%
Return on equity-143.5%
The recordfrom its filings
Filings in 202623
Newest filingOct 16 · DEF 14A
Annual reportAug 31, 2026
Quarterly reportOct 15, 2026
Next report due10-Q by Jan 14
Insider sales, 12 months$0.00
Insider buys, 12 months$200,000
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Aug 2026Revenue $4.3MNet income -$5.0MCash from operations -$4.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Annual report, amended
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.